1000 SPRING ST, SILVER SPRING, MD
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
Investor Presentation
Financial Results, Press Release
Announces Appointment of Kevin J. Tracey to its Board of Directors
Reports Record Third Quarter 2025 Financial Results
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Specialized Disclosure Report
Correspondence
Amended Tender Offer Statement by Third Party